Latest Earnings Results: Q3 '26
Estimated EPS
-$0.31
Reported EPS
-$0.37
Surprise
-21.29%
Estimated Rev
$0M
Reported Rev
---
Surprise
---
Immuneering expects existing cash, cash equivalents and marketable securities as of September 30, 2026 to fund development and operations into fourth quarter of 2028, shortened from 2029.
Bullish Takeaway
Immuneering reported 17.3-month median survival, 36% overall response and 82% disease control in interim pancreatic-cancer data, with no Grade 5 events or new safety signals; MAPKeeper 301 enrollment was ahead of schedule.
Bearish Takeaway
Immuneering shortened its cash runway guidance from 2029 to fourth quarter of 2028, reported higher Q3 R&D expense and net loss, and has not completed registrational trials or approved products.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.40 | -- | -- | N/A |
Q3 '26 | -$0.31 | -$0.37 | -21.29% | MISSED |
Q2 '26 | -$0.26 | -$0.27 | -2.16% | MISSED |
Q1 '26 | -$0.25 | -$0.21 | 16.67% | BEAT |
Q4 '25 | -$0.31 | -$0.18 | 42.39% | BEAT |